Sage — CoQ10 (The Kit)

Hypothesis: CoQ10 is a membrane hinge / ETC shuttle — not a youth molecule. Optional after Fuel · Circadian · Strength. education only; no Rx/stack advice.

The Kit · Coach · Surfer · MB · ETC

**The Metabolic Hypothesis of Coenzyme Q10**

Val Zudans, MD · Frugal Philosophy Essay · September 2026

*This essay presents a metabolic and evolutionary hypothesis for educational and philosophical purposes. It is not medical advice, diagnosis, or treatment. Individual circumstances vary; readers should consult a qualified clinician before making significant changes to diet, lifestyle, or supplementation, especially if they have existing medical conditions or take medications. CoQ10 can interact with warfarin and may affect absorption of other fat-soluble compounds. Nothing here authorizes unsupervised megado**sing. The optional 100–200 mg solubilized-ubiquinone preference stated below is a hypothesis of placement and frugality, not a prescription.*

CoQ10 has become the energy molecule of a captured supplement industry. One camp treats declining coenzyme Q as the cause of fatigue, heart failure, and aging, and sells ubiquinol as if a pre-reduced capsule could restore youthful oxidative phosphorylation to an engine that is no longer asked to work. Another camp treats CoQ10 as a solved vitamin-adjacent story: the body makes it, food supplies a few milligrams, and further supplementation is marketing. Both capture something real. Both miss the upstream constraint.

CoQ10 is not the engine. It is the hinge the engine uses to move electrons from Complex I and II to Complex III, and the redox couple whose oxidized-to-reduced ratio reports whether supply, oxygen, and ATP demand are in register. Raising the number of quinone molecules in plasma does not create oxidative flux, does not rebuild cristae, and does not tell a sedentary, circadian-misaligned, seed-oil-fed organism to demand ATP. It can un-bottleneck an engine that demand, fuel, and inner-membrane conductance have already asked to work. Used first, it is another dashboard intervention.

*The hypothesis is straightforward. Human coenzyme Q economy is a nested-symbiont recycling system whose rate is set by energy flux—the simultaneous throughput of substrate oxidation and ATP turnover—not by the static size of the plasma Q pool or the redox label on a capsule. Oral ubiquinone and ubiquinol are salvage inputs into that membrane pool. They are not substitutes for species-appropriate fuel, circadian entrainment, contractile hormesis, or electron-transport efficiency. Age-related CoQ decline is b**etter understood as the joint product of falling mevalonate-pathway throughput, falling mitochondrial volume, membrane peroxidation, and falling demand than as a primary antioxidant-deficiency event that reduced-form pills can reverse. Ubiquinol is, in substantial part, oxidized in the gut before absorption and then reduced again after it; paying a premium for the reduced label is often paying for a chemical state the stomach and the enterocyte will rewrite. If an optional capsule is used at all after the t**hree-pillar vest, the amount discussed in this hypothesis is 100–200 mg of solubilized ubiquinone in oil, with the fattiest real meal of the feeding window—not megadose dry powder, not branded ubiquinol as a metaphysics, and not a silver bullet taken before fuel, clock, and load.*

Two Dominant Frameworks, and What They Leave Upstream

The first framework is the mitochondrial-antioxidant theory in its popular form. CoQ10 falls with age. The electron-transport chain leaks. Free radicals accumulate. Restore CoQ10, restore the antioxidant shield, restore the youthful organ. Heart-failure trials, statin-myalgia anecdotes, and “cellular energy” marketing are the practical sacraments of that metaphysics. The reduced form, ubiquinol, is sold as the active molecule the aging body can no longer make from ubiquinone.

The second framework is classical nutrition and the incurious reading of endogenous synthesis. CoQ10 is not an essential vitamin. Healthy people synthesize enough. Dietary contribution is a few milligrams a day. Once frank deficiency is excluded—primary biosynthetic defects, severe mitochondrial disease—further supplementation is a low-yield nutraceutical. This view is correct about the absence of a pellagra-style CoQ deficiency in ordinary diets and almost silent about the difference between a pool large enough to keep a resting cell alive and a pool redox state compatible with high-flux oxidative phosphorylation without reverse electron transport.

Both frameworks treat CoQ as a stock. The metabolic hypothesis treats CoQ as a flux hinge. A cell can have a measurable plasma CoQ10 and still be energetically insufficient if the inner-membrane pool is over-reduced, if supercomplexes have disassembled, if cardiolipin has been remodeled by industrial linoleate, if demand is too low to keep ATP synthase turning, or if an expensive ubiquinol capsule was oxidized in gastric acid and then poorly micellarized. Stock assays on a dashboard do not tell you whether the engine is turning.

This is the same category error that runs through the rest of this series. ApoB is a dashboard reading of a starving vascular mitochondrion. Inflammatory cytokines are often compensatory mobilization when ATP generation fails. NAD+ precursors are salvage tickets sold as the voyage. Beauty cues are honest signals of surplus after the engine has paid its maintenance bill. CoQ10, used as first-line anti-aging or first-line “energy,” belongs in that family: it moves a labile plasma pool while leaving fuel mismatch, low energy flux, and electron-transport leak unaddressed.

What CoQ Actually Does

Coenzyme Q10 is a benzoquinone head on a ten-unit isoprene tail. The tail parks the molecule in the inner mitochondrial membrane. The head does the chemistry. Ubiquinone (oxidized) accepts two electrons and two protons and becomes ubiquinol (reduced). Ubiquinol donates those electrons into Complex III. That interconversion is not a side reaction. It is how food electrons become a proton-motive force.

Electrons arrive at the inner membrane as NADH or FADH₂. Complex I oxidizes NADH and reduces ubiquinone. Complex II—succinate dehydrogenase—reduces ubiquinone from the TCA cycle. So do the accessory quinone reductases that link other pathways to the chain: electron-transferring flavoprotein dehydrogenase from fatty-acid β-oxidation, mitochondrial glycerol-3-phosphate dehydrogenase, dihydroorotate dehydrogenase in pyrimidine synthesis, sulfide:quinone oxidoreductase, proline dehydrogenase, choline dehydrogenase. The common product is ubiquinol. Complex III re-oxidizes it through the Q-cycle, reduces cytochrome c, and contributes to the gradient. Complex IV finishes at oxygen. ATP synthase harvests the gradient. ATP synthase remains the toll-keeper. CoQ is how traffic reaches the booth.

The Q-cycle is not a simple handoff. At the Qo site of Complex III, ubiquinol is oxidized in two steps. One electron goes to the Rieske iron-sulfur protein and onward to cytochrome c. The other goes to cytochrome bL, then bH, and reduces a ubiquinone at the Qi site to a semiquinone and then to ubiquinol. Two ubiquinols oxidized at Qo yield one ubiquinol at Qi and two reduced cytochrome c molecules, with protons deposited in the intermembrane space. This is why CoQ is both carrier and participant in proton translocation. A constrained or over-reduced pool does not only slow electron arrival at Complex III. It changes the thermodynamics of the cycle itself.

Two architectural facts follow. First, most CoQ is a mobile pool in the bilayer, not a prosthetic group locked inside one enzyme. Supercomplexes of I+III±IV appear to organize a NADH-facing sub-pool. A more free FADH₂-facing pool serves Complex II and the accessory dehydrogenases. The pools communicate. When fuel selection shifts from carbohydrate (high NADH/FADH₂) to fat (more ETF input), the FADH₂-facing pool can over-reduce. Electrons can then run backward through Complex I, reducing NAD+ and leaking superoxide at the IQ site. Reverse electron transport is a thermodynamic consequence of an over-reduced Q pool plus a high proton-motive force, not a laboratory curiosity. Succinate accumulation is one of the cell’s ways of broadcasting that Q-redox state to the rest of the organism.

Second, the CoQH₂/CoQ ratio is a central bioenergetic sensor. It integrates three variables this series already treats as primary: electron supply from fuel, oxygen tension at Complex IV, and ATP demand as reflected in the proton-motive force. An oxidized pool means the chain can accept electrons. A reduced pool means supply exceeds the capacity to dump electrons to oxygen or to ADP-driven proton return. In obese liver, CoQ synthesis is suppressed, mitochondrial CoQ10 falls, the CoQH₂/CoQ ratio rises, RET-derived hydrogen peroxide increases, and glucose handling deteriorates. Replenishing CoQ10 in that setting can lower the ratio and improve the phenotype in animals—not because CoQ10 is a generic antioxidant sprinkled on damage, but because it restores the oxidized acceptor that Complex I and the fat-oxidation dehydrogenases require.

The same quinone works outside the respiratory chain. DHODH needs it for pyrimidine synthesis. Sulfide oxidation needs it. Parts of amino-acid catabolism need it. A constrained pool therefore does not only lower ATP. It constrains biosynthetic and detoxification pathways that share the acceptor. Primary CoQ deficiency syndromes make this visible: OXPHOS failure plus steroid, pyrimidine, and sulfide phenotypes. Secondary deficiency—aging, statin use, metabolic disease—is milder and patchier. It is the same chemistry at lower amplitude.

CoQ10 is also a chain-breaking antioxidant in membranes, recycling vitamin E and limiting lipid peroxidation. That function is real and downstream. The metabolic hypothesis does not deny it. It refuses to let the antioxidant story occupy the place of the flux story. An over-reduced pool that drives RET will generate more ROS than an adequately oxidized pool of the same size. Adding antioxidant capacity without restoring forward flux is the same category error as megadose nicotinamide: spending a maintenance currency the engine is not earning.

The Recycling Architecture

Humans make CoQ10 in the inner membrane from two pieces: a benzoquinone head derived from tyrosine via 4-hydroxybenzoate, and a decaprenyl tail assembled from isopentenyl pyrophosphate. The tail comes from the mevalonate pathway—the same pathway that makes cholesterol, dolichol, and the prenyl groups on small GTPases. HMG-CoA reductase is the shared gate. Statins close that gate. They lower LDL; they also lower a precursor mitochondria need for their electron carrier. That is not a side effect in the metabolic-hypothesis sense. It is the predictable collision of a dashboard intervention with an engine requirement.

The CoQ synthome is a multi-protein complex (COQ3 through COQ9 and partners) assembled at inner-membrane contact sites. Synthesis is expensive in NADPH and ATP. It declines with age. It is suppressed in obese liver downstream of the mevalonate step. It is vulnerable to any state that starves mitochondria of the redox and energy currency required to build their own hardware. Dietary CoQ10 contributes only a few milligrams a day. Endogenous synthesis is the real supply. Supplementation is an attempt to bypass a biosynthetic bottleneck that the modern metabolic milieu and some of our most common drugs have narrowed.

Once made, CoQ is distributed from the inner membrane to other membranes. How that transport works remains incomplete. What matters for this essay is that oral CoQ10 must survive the gut, enter mixed micelles, ride chylomicrons through lymph, appear in plasma mostly as ubiquinol regardless of what was swallowed, and then find its way into the inner membrane of the tissue that is actually constrained. Plasma total CoQ10 is a transit number. Mitochondrial CoQ content and the CoQH₂/CoQ ratio in that tissue are the engine numbers. Treating a rising plasma kit as restored flux is dashboard thinking.

Nested Symbionts Decide What the Pill Becomes

The eukaryotic cell is not a free-floating metabolic engine. It is a nested symbiont whose energy economy depends on an alphaproteobacterial mitochondrion and an ongoing gut consortium. CoQ lives in the inner membrane of that mitochondrion. The membrane is built from the fatty-acyl species the host eats. The capsule is processed by the same gut that edits NAD precursors into nicotinic acid.

CoQ10 is one of the most hydrophobic molecules in human metabolism. In a capsule it wants to crystallize. Crystals do not enter mixed micelles. Mixed micelles—bile salts, phospholipids, fatty acids—are how the small intestine absorbs fat-soluble molecules. The rate-limiting step for oral CoQ10 is therefore not oxidized versus reduced. It is dissolution into micelles, incorporation into chylomicrons, and exit via lymph. Dry powder in a hard gelatin capsule is a poor tool. Oil-solubilized and crystal-free preparations raise plasma levels several-fold over crystalline powder. Taking any preparation with a fat-containing meal multiplies absorption relative to the fasting state.

Medium-chain triglyceride as a carrier oil is useful because it is already liquid and mixes readily. It is not a sacrament. Olive oil, egg yolk, ruminant fat, or the oil already in a competent softgel perform the same job if the meal supplies bile and mixed micelles. The operational rule is simpler than brand chemistry: CoQ10 with the fattiest real meal of the feeding window, not with black coffee. That rule is the holobiont speaking. Animal fat is already the fuel this series names as proper for the inner symbiont. Using that same fat to carry the quinone is coherence, not a hack.

Reported fractional absorption of a 100 mg dose is often in the low single digits. A capsule that is three percent absorbed delivers on the order of a day’s dietary intake, not a flood. Steady-state plasma rises over days to weeks because the half-life is long. Peak plasma after a dose is typically six to eight hours. None of that peak is proof the inner membrane of a cardiomyocyte or a hepatocyte received the molecule. Tissue uptake in a person who still synthesizes CoQ is modest. Uptake improves when the tissue is already deficient. That is replacement logic, not tonic logic.

Cardiolipin context is the other half of what the pill becomes. The inner membrane that holds the Q pool is packed with cardiolipin. Supercomplex stability, CoQ diffusion, and leak all depend on that lipid environment. Industrial seed-oil linoleate incorporated into membranes is oxidizable, generates 4-HNE adducts on respiratory subunits, and degrades the bilayer in which CoQ is supposed to shuttle. Supplying CoQ10 into a peroxidized, PUFA-rearranged membrane is pouring carrier onto a damaged road. This is why the three pillars are not optional decoration around a supplement. Animal-fat membrane packing and the avoidance of high-linoleic oils are part of making a Q pool that can work.

Energy Flux Sets the Rate, Not the Label on the Bottle

Energy flux, as used in this series, is the rate at which energy moves through the organism: intake and expenditure both high, muscular contraction frequent, ATP turnover rapid, mitochondrial demand real. High flux is not the same as a caloric surplus. Low flux is not the same as a caloric deficit. A person can be in negative energy balance and still be in low flux—restricted, sedentary, hormonally conservative, oxidizing poorly. That is the state in which the Q pool is underused, the synthome is under-driven, and an over-reduced ratio is more likely when fuel is dumped into a chain that ATP synthase is not unloading.

High flux keeps the hinge turning. Contractile work and fasting-feeding transitions raise ATP demand, lower the proton-motive force from its resting high-water mark, and give Complex III a reason to re-oxidize ubiquinol. The pool spends more time able to accept electrons. Mitophagy and biogenesis can be paid for. Low flux does the opposite. Inactivity leaves a high gradient, a chain that is not turning, and a pool that sits reduced when substrate is present. Reverse electron transport becomes cheaper. ROS at IQ becomes a feature. Inflammatory tone and CD38-style NAD drain often rise with the same adiposity. The organism spends maintenance currencies it is no longer earning.

This is why the silver-bullet pattern keeps recurring. Culture looks for the capsule before the bulletproof vest: species-appropriate fuel, morning and evening light, sleep timing, feeding windows, and dynamic resistance or sprint loading in the active circadian phase. Those inputs are free or nearly free. They raise flux. Flux keeps the Q pool cycling. Cycling makes the cheap, solubilized ubiquinone sufficient more often than the ubiquinol billboard admits.

Why the Pool Falls

Age-related CoQ decline is repeatedly measured and repeatedly mis-explained. The metabolic hypothesis names four interlocking causes, none of which is “the molecule got old.”

First, mitochondrial ATP-generating capacity falls: fewer organelles, worse quality, higher heteroplasmy, impaired mitophagy, waning PGC-1α programs, sarcopenia reducing the tissue that both uses and houses CoQ. The membrane that holds the pool shrinks. What remains is often leakier.

Second, biosynthetic throughput falls. The synthome is ATP- and NADPH-expensive. Mevalonate flux is competed for by cholesterol and prenylation. Statins close the shared gate. Aging and inflammatory signals downregulate COQ genes in liver and other tissues. The valve closes.

Third, the membrane environment deteriorates. Seed-oil linoleate and peroxidation products damage cardiolipin and respiratory subunits. A damaged road makes the same amount of carrier less effective and more likely to participate in leak.

Fourth, demand falls while consumption of related maintenance currencies rises. Low contractile flux, circadian flattening, and compensatory inflammation produce a state in which the pool is both under-cycled and over-reduced when substrate is present. Ultra-processed patterns deliver energy without the membrane lipids, nicotinamide dinucleotides, and creatine of animal tissues. Pellagra was low intake. Modern CoQ stress is often high caloric throughput of the wrong substrates, low contractile demand, and a membrane that can no longer host the hinge.

Antioxidant accounts treat the falling pool as a cause of oxidative aging. The metabolic hypothesis treats it as an energetic consequence that then becomes a contributing constraint. Both can be measured. Only one predicts that restoring demand, fuel, and membrane composition will move tissue CoQ function without a pill, and that a pill without those will move plasma CoQ without restoring capacity.

The Forms, Ranked by Mechanism Rather Than Brand

Ubiquinone

Ubiquinone is the oxidized form and the molecule the chain uses as an electron acceptor. It is chemically more stable in air and in acid than ubiquinol. It is the form used in Q-SYMBIO and in much of the heart-failure literature that actually moved hard endpoints. It is also the form named among EnSurf’s ETC-efficiency modulators. Once absorbed, circulating CoQ is reduced to ubiquinol regardless. The body does not leave the quinone in the redox state printed on the bottle.

Ubiquinol

Ubiquinol is the reduced form and the molecule that donates electrons to Complex III. Circulating CoQ in healthy humans is about ninety-five percent ubiquinol. That fact is the sales pitch. The gut is the problem. Ubiquinol is unstable in acid and in air. Simulated gastric and intestinal conditions, and dog studies of commercial ubiquinol capsules, show a large fraction oxidized to ubiquinone before the contents reach the absorptive epithelium. In those experiments most of what the enterocyte sees is ubiquinone, even if the label said ubiquinol. Lymph and plasma then reduce it again. Mouse data are less dramatic—both forms can arrive in the lumen still in their original redox state—but they do not rescue the marketing story. They show that form preservation is formulation- and species-dependent, not a law of nature that makes ubiquinol inherently superior.

Boundaries

Optional 100–200 mg solubilized ubiquinone placement (not a prescription). No ubiquinol-as-personality / 600 mg forum heart-failure scale-down. Map ≠ terrain. Board first: Fuel · Circadian · Strength · ETC; Kit last.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.

← Kit hub · NAD precursors · MB

Related: Sage — A Metabolic Hypothesis of Ocular Surface Disease (Wipeouts · Ophthalmology).